Skip to main content
. Author manuscript; available in PMC: 2023 Jan 1.
Published in final edited form as: Cancer J. 2022 May-Jun;28(3):208–223. doi: 10.1097/PPO.0000000000000591

Figure 18.

Figure 18

Comparison of incidence of new onset diabetes mellitus from hormone replacement therapy and statin therapy. Data reported from individual statin randomized controlled trials and meta-analyses of statin randomized controlled trials show increased risk of new onset diabetes mellitus that exceeds rare level of risk with statin therapy. In contrast, individual hormone replacement randomized controlled trials and meta-analyses of hormone replacement randomized controlled trials show decreased risk of new onset diabetes mellitus with hormone replacement therapy. Absolute risk of 10 cases/10,000 women is delineated to show relation of new onset diabetes mellitus to the category of rare frequency of events (Table 4). RCT = randomized controlled trial; meta = meta-analysis; JUPITER = Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin; WHI = Women’s Health Initiative; WHI-CEE = Women’s Health Initiative-conjugated equine estrogen; WHI-CEE+MPA = Women’s Health Initiative-conjugated equine estrogen plus medroxyprogesterone acetate; HERS = Heart and Estrogen/progestin Replacement Study; HRT = hormone replacement therapy